AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 11 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Cryopreservation of human dendritic cells should not reduce their efficacy in cancer vaccines, researchers in Germany have found.
"In the past decade there has been increasing evidence that tumor antigen-loaded dendritic cells (DC) are able to elicit anti-tumor T-cell responses," explained Joerg Westermann and colleagues at Humboldt University's and the Max Delbrueck Center for Molecular Medicine in Berlin. "Since GMP production of DC for clinical vaccination protocols is a time- and cost-intensive procedure, cryopreservation of DC in aliquots ready for clinical use would significantly facilitate DC-based vaccination in the clinic."
Frozen DC retained their structural and functional integrity, Westermann and coauthors found.
The researchers subjected DC collected from chronic myeloid leukemia (CML) patients to a standard cryopreservation procedure. The frozen cells remained viable after thawing and showed no morphological changes, they reported.
FACS profile analysis indicated no immunophenotypical alterations in cryopreserved DC, study data showed. ...
Source: HighBeam Research, Cryopreservation does not lower dendritic cell immunogenicity.